Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.

Takashi ItoHiromi NagashimaMasachika AkiyamaYu UtsumiHideomi SatoShinji ChibaMayu SugaiKenji UbeYoshiaki MoriKana WatanabeTatsuro FukuharaMakoto Maemondo

Published in: Thoracic cancer (2021)

ICI treatment tends to have better efficacy in patients with L858R-mutated tumors. This study suggests that patients with L858R-mutated NSCLC are candidates for ICI treatment after EGFR-TKI treatment.

Keyphrases

small cell lung cancer
tyrosine kinase
epidermal growth factor receptor
replacement therapy
brain metastases